Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 146pembrolizumab 118Magnetic Resonance Spectroscopy 117Cyclophosphamide 113Biopsy 96fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46Radiotherapy 41venetoclax 40Cetuximab 40fludarabine phosphate 39Paclitaxel 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 32Oxaliplatin 27Leucovorin 27Dexamethasone 26durvalumab 25X-Rays 25Irinotecan 25Radiation 24Cytarabine 23Azacitidine 23Injections 22Temozolomide 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × JNJ-64264681 × 90 days × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡